News for Aurinia Pharmaceuticals Stock (AUPH)

TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 06/10/22

AUPH SHAREHOLDER ALERT: Jakubowitz Law Reminds Aurinia Pharmaceuticals Inc. Shareholders of a Lead Plaintiff Deadline of June 14, 2022

PRNewsWire • 06/10/22

DEADLINE NEXT TUESDAY: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPH

Newsfile Corp • 06/10/22

TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 06/09/22

AUPH LAWSUIT ALERT: Levi & Korsinsky Notifies Aurinia Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PRNewsWire • 06/09/22

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aurinia Pharmaceuticals Inc., of Class Action Lawsuit and Upcoming Deadline - AUPH

PRNewsWire • 06/09/22

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aurinia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 14, 2022 - (NASDAQ: AUPH)

PRNewsWire • 06/08/22

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

Business Wire • 06/03/22

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 06/01/22

ROSEN, A LEADING AND RANKED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

PRNewsWire • 05/31/22

Aurinia Pharmaceuticals Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 14, 2022 to Discuss Your Rights - AUPH

Newsfile Corp • 05/30/22

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 05/30/22

AUPH INVESTOR NOTICE: TOP RANKED ROSEN LAW FIRM Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Newsfile Corp • 05/28/22

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 05/27/22

ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Newsfile Corp • 05/26/22

AURINIA PHARMACEUTICALS INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Aurinia Pharmaceuti

PRNewsWire • 05/26/22

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 05/25/22

AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. Limited Shareholders

Newsfile Corp • 05/24/22

AUPH INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

PRNewsWire • 05/24/22

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 05/23/22

ROSEN, Top Ranked Investor Counsel, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Newsfile Corp • 05/21/22

Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval

Seeking Alpha • 05/20/22

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

Business Wire • 05/20/22

ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Newsfile Corp • 05/18/22

UPCOMING AUPH DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

PRNewsWire • 05/18/22